Werewolf Therapeutics (HOWL) Interest Expenses (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Interest Expenses of $475000.0 for Q2 2026, down 63.49% year-over-year from $1.3 million in Q2 2025, and down 65.28% on a QoQ basis from $1.4 million in Q1 2026.
Werewolf Therapeutics (HOWL) Interest Expenses (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Interest Expenses for 6 years, with the latest figure at $475000.0 in Q2 2026.
- Interest Expenses for Q2 2026 came in at $475000.0, down 63.49% year-over-year; the trailing twelve-month figure through Jun 2026 was $4.5 million (up 19.49% YoY), and the FY2025 annual result was $86.6 million, up 27.79% from the prior year.
- Interest Expenses eased to $475000.0 in Q2 2026, from $1.4 million in the prior quarter.
- Over five years, Interest Expenses peaked at $2.3 million in Q3 2025 and troughed at -$31000.0 in Q4 2024.
- A 4-year average of $1.0 million and a median of $1.1 million in 2023 frame the typical range for Interest Expenses.
- The widest annual swing landed in 2024, when Interest Expenses sank 103.07%; it then jumped 4516.13% in 2025.
- A 4-year view of Interest Expenses shows it stood at $1.0 million in 2023, then sank by 103.07% to -$31000.0 in 2024, then jumped by 4516.13% to $1.4 million in 2025, then plunged by 65.3% to $475000.0 in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $475000.0 in Q2 2026, $1.4 million in Q1 2026, and $1.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 475,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 475,000.00 |
| Jun 30, 2026 | 475,000.00 |
| Mar 31, 2026 | 1.37 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 2.92 Mn |
| Dec 31, 2025 | 2.92 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |